Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

Novartis

Pacific Biosciences of California

Regeneron Pharmaceuticals

Roche Holding AG

Takeda Pharmaceutical

Teladoc

Twist Bioscience Corp

Vertex Pharmaceuticals

Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.

ARKG: Precautionary Measures, But Transformational Objectives Remain Intact

WALTHAM, Mass., Feb. 18, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing...

Thermo Fisher Scientific Recognized with Six CMO Leadership Awards

CARLSBAD, Calif., Feb. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today launched its CE-IVD-Marked, Applied Biosystems TaqPath COVID–19 HT Kit that is compatible with the Amplitude platform. The high-throughput solution enables clinical and...

Thermo Fisher Scientific Launches CE-IVD-Marked High Throughput COVID-19 Diagnostic Assay for Use On Its Automated Amplitude Platform

WALTHAM, Mass., Feb. 3, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher's Gibco CTS Dynabeads CD3/CD28. The...

Thermo Fisher Scientific and JW Therapeutics Announce CAR-T Partnership in China

Ford Motor Company

Gogo

Ford, UPS, Thermo Fisher and Gogo were our top stock trades for Tuesday. Now, let's pull up the charts have a look at what's going on.

4 Top Stock Trades for Tuesday: F, UPS, TMO, GOGO

Thermo Fisher Scientific Inc. (TMO) CEO Marc Casper on Q4 2020 Results - Earnings Call Transcript

Thermo Fisher (TMO) records $3.2 billion of COVID-19 response revenues and accelerated growth in base business in Q4.

Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments

The company's COVID-19 testing continued to be a huge growth driver.

How Thermo Fisher Scientific Beat Wall Street Estimates in Q4

Thermo Fisher (TMO) delivered earnings and revenue surprises of 3.35% and 2.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Top Estimates

Shares of Thermo Fisher Scientific (NYSE:TMO) rose 0.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 99.72% over the past year to $7.09, which beat the estimate of $6.56.

Thermo Fisher Scientific: Q4 Earnings Insights

Thermo Fisher Scientific Inc. (NYSE: TMO) reported its financial results for the fiscal fourth quarter on Monday that topped analysts' estimates for earnings and revenue. In related news, Vertex Pharmaceuticals is also scheduled to publish its Q4 earnings report on Monday after market close.

Thermo Fisher tops Wall Street estimates in the fiscal fourth quarter

Shares of Thermo Fisher Scientific Inc. surged 2.2% in premarket trading Monday, after the health care diagnostics and therapies company reported a big earnings beat and revenue that soared to more than $10 billion for the first time. Net income rose to $2.50 billion, or $6.24 a share, from $1.00 billion, or $2.49 a share, in the year-ago period.

Thermo Fisher's stock rallies after big earnings beat, as revenue jumps above $10 billion

WALTHAM, Mass., Feb. 1, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter and Full Year 2020 Highlights Fourth quarter...

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2020 Results

Companies working in telehealth, at-home testing, and back-to-work solutions might just win the day -- and in fact, the whole year.

Healthcare Trends That Will Rule 2021

On Monday, February 01, Thermo Fisher Scientific (NYSE:TMO) will release its latest earnings report. Benzinga's outlook for Thermo Fisher Scientific is included in the following report.

Earnings Outlook for Thermo Fisher Scientific

Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Thermo Fisher (TMO) Ahead of Earnings?

Thermo Fisher's (TMO) Life-Science Solutions and Specialty Diagnostics segments are expected to have contributed, banking on COVID-19-led growing healthcare needs.

Thermo Fisher (TMO) to Report Q4 Earnings: What's in Store?

Baxter

Boston Scientific

Medtronic

Stryker

The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.

This Medical Device Maker Will Be Well Positioned Post COVID

Shares of Thermo Fisher Scientific Inc. are up 1.3% in premarket trading on Tuesday after the company said it will spend $450 million in cash to acquire Mesa Biotech Inc., a privately held medical testing company. It will also pay the company up to $100 million in additional milestone payments.

Thermo Fisher to acquire company with COVID-19 test

The addition of Henogen's manufacturing capabilities in Europe complement Thermo Fisher's (TMO) four development and manufacturing sites in North America.

Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout

WALTHAM, Mass. and LYON, France, Jan. 15, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc., (NYSE: TMO), the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry, today announced that Thermo...

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

Abbott Labs

Becton, Dickinson and Co.

AdvisorShares Focused Equity ETF

Eagle Bancorp

Globe Life Inc

HEICO

Hormel Foods

Miller Industries

RPM International

Zoetis

Welcome to Alpha Trader. We have a special double bill today in honor of wildcard weekend coming up on the show. Eddy Elfenbein of Crossing Wall Street giving us his top five new stocks for 2021. But first we are pleased to welcome back to the show, Ryan Detrick. He is Chief Market Strategist for LPL Financial. Ryan, welcome back to Alpha Trader.

The 2021 Market Outlook And Some New Stock Picks - Ryan Detrick And Eddy Elfenbein Join Alpha Trader (Podcast Transcript)

Thermo Fisher (TMO) launches Amplitude Solution to automate high-throughput PCR-based testing and significantly expands capacity for viral transport media production in Europe.

Thermo Fisher (TMO) Rides on End Market Growth Amid Pandemic

CARLSBAD, Calif., Jan. 14, 2021 /PRNewswire/ -- As scientists continue to identify new strains of the SARS-CoV-2 virus, including the B.1.1.7 UK variant that studies suggest is more transmissible, genetic sequencing is being used to track these strains and new ones that are emerging, as...

Thermo Fisher Scientific Extends SARS-CoV-2 GlobalAccess Sequencing Program to Support Research on New Virus Strains

This week's Alpha Trader podcast features hosts Aaron Task and Stephen Alpher speaking with LPL Financial's Ryan Detrick and Eddy Elfenbein, editor of the Crossing Wall Street blog and portfolio manager of the AdvisorShares Focused Equity ETF (CWS).

News for Thermo Fisher Scientific Stock (TMO)